- Report
- July 2024
- 136 Pages
Global
From €2730EUR$2,999USD£2,318GBP
- Report
- May 2024
- 139 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Report
- May 2024
- 134 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Report
- May 2024
- 170 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- April 2025
- 200 Pages
Global
From €7236EUR$7,950USD£6,146GBP
- Clinical Trials
- April 2025
- 240 Pages
Global
From €2731EUR$3,000USD£2,319GBP
- Clinical Trials
- April 2025
- 50 Pages
Global
From €1365EUR$1,500USD£1,160GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1365EUR$1,500USD£1,160GBP
- Report
- April 2025
- 200 Pages
Global
From €7236EUR$7,950USD£6,146GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €2275EUR$2,500USD£1,933GBP
- Clinical Trials
- April 2025
- 100 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1365EUR$1,500USD£1,160GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1365EUR$1,500USD£1,160GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1365EUR$1,500USD£1,160GBP
- Drug Pipelines
- April 2025
- 40 Pages
Global
From €1138EUR$1,250USD£966GBP
- Report
- August 2024
- 60 Pages
Global
From €1365EUR$1,500USD£1,160GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3413EUR$3,750USD£2,899GBP
- Report
- July 2024
- 231 Pages
Global
From €7236EUR$7,950USD£6,146GBP
- Report
- July 2024
- 200 Pages
Global
From €4504EUR$4,949USD£3,826GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more